Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17190455 | 0.88 | MAPT (0.31) | MAPT | |
| SCHEMBL21538040 | 0.88 | MAPT (0.31) | MAPT | |
| SCHEMBL23016251 | 0.85 | CYP3A4 (0.31) | MAPT | |
| SCHEMBL21538039 | 0.85 | CYP3A4 (0.31) | MAPT | |
| SCHEMBL23183552 | 0.85 | EPHX1 (0.42) | MAPT | |
| SCHEMBL17192577 | 0.84 | MAPT (0.33) | MAPT | |
| SCHEMBL15748651 | 0.84 | MAPT (0.34) | MAPTCHRM1 | |
| SCHEMBL24268412 | 0.84 | MAPT (0.40) | MAPTCHRM1 | |
| SCHEMBL22821409 | 0.81 | MAPT (0.32) | MAPTCHRM1 | |
| SCHEMBL17192582 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-9421274-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2016-04-21 | — | — | US | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | MAPT 2466/4885CHRM1 4375/4885 |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | MAPT 2604/4885CHRM1 1892/4885 |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KIT, JMJD7, TPSB2 | MAPT 4090/4885CHRM1 2584/4885 |
| US-20160106859-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | MAPT 2466/4885CHRM1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.